Efficacy of Granulocyte-Colony Stimulating Factor (G-CSF)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

155 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-19

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to analyze the clinical factors associated with the effect of Granulocyte-Colony Stimulating Factor (G-CSF).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients

NCT03793205

Gynecologic Cancer Myelosuppression Adult Febrile Neutropenia +1 more

UNKNOWN PHASE4

Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study

NCT01763398

Non-Hodgkin's Lymphoma

COMPLETED

Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

NCT06711523

Neutropenia, Chemotherapy-Induced Febrile Breast Neoplasm Female

ACTIVE_NOT_RECRUITING PHASE3

G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy

NCT00770172

Chemotherapeutic Agent Toxicity Neutropenia Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE3

Evaluation and Modeling of the G-CSF Effect on the Evolution of Neutrophils During Chemotherapy Based on Eribulin

NCT02841722

Breast Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Granulocyte-Colony Stimulating Factor (G-CSF) G-CSF is known to be a synthetic cytokine that induces neutrophil differentiation and proliferation survival during leukocyte differentiation, and increases the activity in the periphery of mature neutrophils, which play an important role in human immunity. Cytotoxic chemotherapy inhibits bone marrow hematopoiesis. Inhibition of bone marrow hematopoiesis causes anemia, thrombocytopenia and leukopenia, and significant leukocytopenia causes opportunistic infection. G-CSF is an indispensable drug for the treatment of leukopenia caused by cytotoxic chemotherapy in solid and blood cancer patients receiving chemotherapy.
2. Chemotherapy with chemotherapy and G-CSF The severity of neutropenia induced by chemotherapy was grade 1 (\<1500 / mm3), grade 2 (\<1500-1000 / mm3) and grade 3 (\<1000) based on the Common Terminology Criteria for Adverse Events To 500 / mm3) and grade 4 (\<500 / mm3). Cytotoxic anticancer drugs used in general chemotherapy cause neutropenia, and febrile neutropenia occurs in 10-20% of patients. In order to recover this, grade 4 neutropenia with an absolute neutrophil count (ANC) of less than 500 and neutrophil to grade 2 or higher with G-CSF in case of febrile grade 3 neutropenia.
3. G-CSF dose and timing G-CSF (Renoglass team lenograstim 250 ug) was subcutaneously injected to a solid tumor (grade 3 or higher regardless of fever) with grade 3 or grade 4 neutropenia with fever Until then, take medication daily. It is used regardless of gender, age, weight, body mass index, method of using anticancer, and injection time.

However, the actual timing and extent of neutrophil recovery after G-CSF administration varies from patient to patient. G-CSF is a cytokine that is currently used in clinical trials. However, there are insufficient studies to investigate the clinical factors involved in the recovery of neutrophils in bone marrow after G-CSF administration in domestic cancer patients. Therefore, this study aims to analyze the clinical factors for the recovery of bone marrow hematopoietic function of G-CSF administered in neutropenia following cytotoxic chemotherapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neutropenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

neutropenia after cytotoxic chemotherapy

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neutropenia in chemotherapy

Neutropenia after cytotoxic chemotherapy

Group Type EXPERIMENTAL

lenograstim

Intervention Type DRUG

injection of lenograstim in patients with neutropenia after cytotoxic chemotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

lenograstim

injection of lenograstim in patients with neutropenia after cytotoxic chemotherapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients diagnosed with solid cancer and blood cancer
2. Patients who received chemotherapy with moderate risk (Appendix 1, Appendix 2)
3. CTCAE version 4.0 showed grade 4 neutropenia, grade 3 neutropenia (blood cancer), Decreased grade 3 neutrophils with fever (solid cancer)
4. Those who understand and agree with the purpose of the research

Exclusion Criteria

* 1\) Patients with hypersensitivity to G-CSF 2) Patients not diagnosed with hematologic tumor 3) grade 1, grade 2 or more neutropenia 4) Patients who did not sign a consent agreement

Eligible Sex

ALL

Accepts Healthy Volunteers

No